within Pharmacolibrary.Drugs.ATC.N;

model N01AH01
  extends Pharmacokinetic.Models.PK_3C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0006666666666666666,
    adminDuration  = 600,
    adminMass      = 0.005 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N01AH01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Fentanyl is a potent synthetic opioid analgesic, primarily used in anesthesia and for managing severe pain. It acts mainly as a μ-opioid receptor agonist, providing profound analgesia and sedation. Fentanyl is approved and widely used today both in acute settings (e.g., perioperative, ICU) and for chronic pain, often as transdermal patches or intravenous injections.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, both sexes, aged approx. 20-40 years, after single intravenous dose.</p><h4>References</h4><ol><li><p>Ziesenitz, VC, et al., &amp; van den Anker, JN (2018). Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. <i>Clinical pharmacokinetics</i> 57(2) 125–149. DOI:<a href=\"https://doi.org/10.1007/s40262-017-0569-6\">10.1007/s40262-017-0569-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28688027/\">https://pubmed.ncbi.nlm.nih.gov/28688027</a></p></li><li><p>Scholz, J, et al., &amp; Schulz, M (1996). Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. <i>Clinical pharmacokinetics</i> 31(4) 275–292. DOI:<a href=\"https://doi.org/10.2165/00003088-199631040-00004\">10.2165/00003088-199631040-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8896944/\">https://pubmed.ncbi.nlm.nih.gov/8896944</a></p></li><li><p>Lötsch, J, et al., &amp; Geisslinger, G (2013). Pharmacokinetics of non-intravenous formulations of fentanyl. <i>Clinical pharmacokinetics</i> 52(1) 23–36. DOI:<a href=\"https://doi.org/10.1007/s40262-012-0016-7\">10.1007/s40262-012-0016-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23100195/\">https://pubmed.ncbi.nlm.nih.gov/23100195</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N01AH01;
